Hematologic

Viewing Page 2 of 6 | Showing Results 11 - 20 of 51

CML CA180-653 Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

This non-interventional, prospective study will characterize the impact of three approved first and second generation BCR-ABL1 tyrosine kinase...

Ajay Kundra, M.D.
  • Providence Regional Cancer Partnership - Everett

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Inclusion Criteria:Subject must have a diagnosis of primary or secondary wAIHA as documented by a positive direct antiglobulin test (DAT) specific...

Livia Hegerova, M.D.
  • Swedish Medical Center

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma

Inclusion Criteria:Relapsed or refractory hematologic malignancy (lymphoma or multiple myeloma) that has progressed, or is currently progressing...

Krish Patel, M.D.
  • Swedish Medical Center

Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias

Inclusion Criteria:Participant must have relapsed/refractory AML and exhausted standard available therapies known to provide clinical...

Raya Mawad, M.D.
  • Swedish Medical Center

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)

This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of lisocabtagene maraleucel (JCAR017) in adult subjects who...

John Godwin, M.D.
  • Providence Cancer Institute Franz Clinic

CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY

The purpose of the Connect MDS/AML Disease Registry is to provide unique insights into treatment regimens and sequencing of these regimens as they...

James Cunningham, M.D.
  • Providence St. Mary Regional Cancer Center
  • Walla Walla Research

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaInclusion Criteria:• Males and females greater than or equal to 18...

Krish Patel, M.D.
  • Swedish Medical Center

DFC PCYC-1141-CA - A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)

Inclusion Criteria:•Histologically confirmed diagnosis of follicular lymphoma CD20+ (Grade 1, 2 or 3a) Ann Arbor Stage II, III or IV...

Raul Mena, M.D.
  • Disney Family Cancer Center (DFCC)
  • John Wayne Cancer Institute (JWCI)
  • Providence Los Angeles Research Center

A PHASE 3B RANDOMIZED STUDY OF LENALIDOMIDE (CC-5013) PLUS RITUXIMAB MAINTENANCE THERAPY FOLLOWED BY LENALIDOMIDE SINGLE-AGENT MAINTENANCY VERSUS RITUXIMAB MAINTENANCE IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR, MARGINAL ZONE OR MANTLE CELL LYMPHOMA

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL. Lenalidomide is...

James Cunningham, M.D.
  • Providence St. Mary Regional Cancer Center
  • Walla Walla Research
Viewing Page 2 of 6 | Showing Results 11 - 20 of 51